Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 3, 2008, Pages 289-296

  Viganò, Alessandra ^a   Zuccotti, Gian Vincenzo ^a   Pacei, Michela ^b   Erba, Paola ^a   Castelletti, Eleonora ^b   Giacomet, Vania ^a   Amendola, Antonella ^b   Pariani, Elena ^b   Tanzi, Elisabetta ^b   Clerici, Mario ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

HIV infection; Immunology; Influenza; Pediatrics; Vaccine

Indexed keywords

ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G3 ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 2; VIROSOME; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ANTIBODY;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MALAISE; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; T LYMPHOCYTE; TH1 CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; IMMUNOLOGY; VIRUS LOAD;

ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; INFLUENZA VACCINES; MALE; VIRAL LOAD;

EID: 47049113479     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181632cda     Document Type: Article

References (60)

1. Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease. Immunol Rev. 1997;159:31-48.
2. Shearer GM. HIV-induced immunopathogenesis. Immunity. 1998;9:587-593.
3. Simon V, Ho DD, Karim QA. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368:489-504.
4. Saag MS. The impact of highly active antiretroviral therapy on HIV-specific immune function. AIDS. 2001;15(Suppl 2):S4-S10.
5. Lederman MM. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS. 2001;15(Suppl 2):S11-S15.
6. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies - implications for clinical management. JAMA. 2000;284:223-228.
7. Cooper DA. Immunological effects of antiretroviral therapy. Antivir Ther. 1998;3:19-23.
8. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
9. Trabattoni D, Piconi S, Biasin M, et al. Granule-dependent mechanisms of lysis are defective in CD8+ T cells of HIV-infected, antiviral therapy-treated individuals. AIDS. 2004;18:859-869.
10. Clerici M, Saresella M, Trabattoni D, et al. Thymic volume predicts long term immune reconstitution in HIV-infected, HAART-treated children. AIDS. 2002;16:2219-2221.
11. Viganò A, Vella S, Principi N, et al. Thymus volume correlates with the progression of vertical HIV infection. AIDS. 1999;13:F29-F35.
12. Resino S, Abad ML, Navarro J, et al. Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clin Exp Immunol. 2003;131:130-137.
13. Kalayjian RC, Landay A, Pollard RB, et al. Age-related immune dysfunction in health and in HIV disease: association of age and HIV infection with naïve CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis. 2003;187:1924-1933.
14. Kalayjian RC, Spritzler J, Pu M, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis. 2005;192:1577-1587.
15. Hakim FT, Memon SA, Cepeda R, et al. Age-dependent incidence, time course, and consequence on thymic renewal in adults. J Clin Invest. 2005; 115:930-939.
16. Gibb DM, Newberry A, Klein N, et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet. 2000; 355:1331-1332.
17. Texeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15:1749-1756.
18. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in patients with HIV infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis. 2000;181:141-147.
19. Douek DC, Koup RA, McFarland RD, et al. Effect of HIV on thymic function before and after antiretroviral therapy in children. J Infect Dis. 2000;181:1479-1482.
20. Falcó V, Jordano Q, Cruz MJ, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine. 2006;24:2567-2574.
21. Amendola A, Tanzi E, Zappa A, et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine. 2002;20:3720-3724.
22. Berkelhamer S, Borocj E, Elsen C, et al. Effect of highly active antiretroviral therapy on the serologic response to additional measles vaccination in HIV-infected children. Clin Infect Dis. 2001;32:1090-1094.
23. Lima M, Succi de Menezes RC, Nunes Dos Santos AM, et al. Rubella immunization in HIV-1-infected children, cause for concerns in vaccination strategies. Pediatr Infect Dis J. 2004;23:604-607.
24. Rosenblatt HM, Song LY, Nachman SA, et al. Tetanus immunity after diphtheria, tetanus toxoid, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol. 2005;116: 698-703.
25. Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol. 2000;65:644-648.
26. Zanetti AR, Amendola A, Besana S, et al. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2006;24: B29-B32.
27. Tanzi E, Esposito S, Bojanin J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol. 2006;78:440-445.
28. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine. 2000;18:3040-3049.
29. Jackson CR, Vavro CL, Valentine M, et al. Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with HIV. Pediatr Infect Dis J. 1997;16:200-204.
30. Kroon FP, Rimmelzwaan GF, Roos MTL, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12:F217-F223.
31. Fuller JD, Craven DE, Steger KA, et al. Influenza vaccination of HIV-infected adults: impact of plasma levels of HIV type 1 RNA and determinants of antibody responses. Clin Infect Dis. 1999;28:541-547.
32. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS. 1997;11:1013-1021.
33. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis. 2005;191: 1442-1450.
34. World Health Organization. Recommendations for the use of inactivated influenza vaccines and other preventive measures. Wkly Epidemiol Rec. 2000;75:281-288.
35. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2005;54:1-40.
36. Schaad UB, Buhlmann U, Burger R, et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis. Antimicrob Agents Chemother. 2000;44:1163-1167.
37. Zuccotti GV, Cucchi C, Sala D, et al. Immunogenicity and safety of a virosomal influenza vaccine in HIV-infected children. Acta Paediatr. 2002;91:486-487.
38. Herzog C, Metcalfe IC, Schaad UB. Virosome influenza vaccine in children. Vaccine. 2002;20S5:24-28.
39. Kanra G, Marchisio P, Feiterna-Sperling C, et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J. 2004;23:300-306.
40. Salleras L, Dominguez A, Pumarola T, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine. 2006;24:6638-6642.
41. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992;41S1:B1-B19.
42. Huckriede A, Bungener L, Stegmann T, et al. The virosome concept for influenza vaccines. Vaccine. 2005;23:26-28.
43. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev Vaccines. 2003;2:189-196.
44. Dowdle WA, Kendal AP, Noble GR. Influenza viruses. In: Lennette EM, Schmidt NJ, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Washington, DC: American Public Health Association; 1979:585-609.
45. The European Agency for the Evaluation of Medical Products (EMEA), Committee for Proprietary Medical Products (CPMP). Note for Guidance on Harmonization of Requirements for Influenza Vaccine (CPMP/BWP/ 214/96). London; 1997.
46. Kroon FP, van Dissel JT, Ravensbergen E, et al. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 1999;18: 524-530.
47. Talesnik E, Vial PA, Labarca J, et al. Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 19:471-477.
48. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS. 1994;8:469-476.
49. King JC, Vink PE, Chang I, et al. Antibody titers eight months after three doses of a five-valent pneumococcal conjugate vaccine in HIV and non-HIV-infected children less than two years of age. Vaccine. 1998;16:361-365.
50. Fiore AE, Shay DK, Haber P, et al. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committe on Immunization Practices (ACIP), 2007. MMWR Recomm Rep. 2007;56(RR-6):1-54.
51. Miedema F, Petit AJ, Terpstra FG. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest. 1988;82:1908-1916.
52. Clerici M, Stocks NI, Zajac RC, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest. 1989;84:1892-1899.
53. Viganò A, Dally L, Bricalli D, et al. An 18 months clinical and immunovirologic characterization of the efficacy of stavudine, lamivudine and indinavir in pediatric HIV infection. J Pediatr. 1999;135:675-682.
54. Resino S, Galan I, Perez A, et al. HIV-infected children with moderate/ severe immune suppression: changes in the immune system after highly active antiretroviral therapy. Clin Exp Immunol. 2004;137:570-577.
55. Cambier JC. Signal transduction by T and B cell antigen receptors: converging structures and concepts. Curr Opin Immunol. 1992;4:257-264.
56. Clerici M, Landay AL, Kessler HA, et al. Multiple patterns of alloantigen presenting/stimulating cell dysfunction in HIV infected individuals. J Immunol. 1991;146:2207-2213.
57. Wabe MR, Forni L, Loor F. Switch in immunoglobulin class production observed in single clones of committed lymphocytes. Science. 1978;199: 1070-1080.
58. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol. 1990;8:303-333.
59. Coffman RL, Lebman DA, Rothman P. Mechanism and regulation of immunoglobulin isotype switching. Adv Immunol. 1993;54:229-270.
60. Germann T, Bongartz M, Dlugonska H, et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol. 1995;25: 823-829.